Opportunity Information: Apply for PAR 14 206
Apply for PAR 14 206
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "HIV Vaccine Research and Design (HIVRAD) Program (P01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on May 5, 2014 and posted on May 5, 2014.
- Applicants must submit their applications by Jul 29, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $5,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Small businesses Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) State governments For profit organizations other than small businesses City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The HIV Vaccine Research and Design (HIVRAD) Program (P01) grant opportunity, listed as PAR-14-206, was a National Institutes of Health (NIH) Funding Opportunity Announcement aimed at advancing the discovery-stage science needed to create a preventive (prophylactic) HIV/AIDS vaccine. The core idea of the program was to fund large, coordinated research efforts that bring together multiple scientific components under one umbrella, rather than supporting isolated single-project studies. By using the P01 mechanism, NIH was signaling that it wanted tightly integrated, multi-project teams that can tackle major questions in HIV vaccine design through complementary approaches, shared resources, and coordinated leadership.
The scientific focus was AIDS prophylactic vaccine discovery research, meaning the program emphasized upstream work that helps define and validate vaccine concepts before they move into later-stage clinical testing. The FOA specifically highlighted the value of multi-disciplinary collaboration, which in the HIV vaccine field typically involves immunology, virology, structural biology, protein engineering, antibody and B cell biology, computational or systems approaches, and translational studies that connect lab findings to realistic vaccine strategies. A notable feature of this opportunity is that it explicitly allowed extensive modeling of vaccine concepts in non-human primates, reflecting the importance of primate studies for evaluating immune responses, protection signals, and candidate vaccine performance in a model more comparable to humans than small animals.
Administratively, this was a discretionary grant opportunity using the NIH grant funding instrument, categorized under health-related research. The relevant CFDA numbers were 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research), which are commonly associated with NIH/NIAID-supported infectious disease and immunology programs. The announcement was posted on May 5, 2014, and had an original and final closing date of July 29, 2014, with an archive date of August 29, 2014. The estimated total funding available was listed at $5,000,000, indicating NIH expected to support a limited number of sizeable, collaborative awards rather than many small grants. There was no cost sharing or matching requirement, which is typical for NIH research grants and lowers barriers for applicants by not requiring institutional co-funding.
Eligibility was broad and inclusive across many organization types. Domestic applicants included public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (including small businesses and other for-profits), state and local governments (including city or township governments, county governments, special district governments), and public housing authorities/Indian housing authorities. The FOA also explicitly included tribal entities and tribal-serving or minority-serving institutions, such as Federally recognized tribal governments, tribal organizations that are not Federally recognized, Tribally Controlled Colleges and Universities (TCCUs), Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Faith-based and community-based organizations were also listed as eligible, as were eligible agencies of the Federal Government.
Importantly, the opportunity allowed non-U.S. participation in multiple forms. Non-domestic (non-U.S.) entities (foreign organizations) and non-domestic (non-U.S.) foreign institutions were eligible to apply. In addition, non-U.S. components of U.S. organizations could participate, and foreign components were permitted as defined in the NIH Grants Policy Statement. This matters in HIV vaccine research because critical expertise, cohorts, and research infrastructure often span multiple countries, and NIH commonly supports international collaboration when it is scientifically justified.
For applicants or readers seeking the authoritative details, NIH provided a direct link to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-14-206.html. For technical issues accessing the announcement or linking to it, the contact point listed was the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV. Overall, the HIVRAD P01 opportunity can be understood as NIH funding meant to accelerate innovative, team-based HIV vaccine discovery by supporting integrated research programs capable of addressing high-impact scientific problems and, when appropriate, testing vaccine ideas rigorously in non-human primate models.
FAQs: HIV Vaccine Research and Design (HIVRAD) Program (P01) - PAR-14-206
What is the HIV Vaccine Research and Design (HIVRAD) Program (P01) opportunity?
HIVRAD (P01), listed as PAR-14-206, was a National Institutes of Health (NIH) Funding Opportunity Announcement (FOA) designed to advance discovery-stage science needed to create a preventive (prophylactic) HIV/AIDS vaccine. It emphasized coordinated, team-based research rather than isolated single-project studies.
Which NIH grant mechanism was used for this opportunity?
This FOA used the NIH P01 mechanism, which is intended for large, integrated, multi-project research programs that operate under coordinated leadership and often share resources across projects.
What was NIH trying to achieve by using a P01 mechanism instead of single-project awards?
NIH signaled a preference for tightly integrated, multi-project teams that could tackle major questions in HIV vaccine design through complementary approaches, shared resources, and coordinated leadership, rather than funding separate, unconnected projects.
What scientific area did PAR-14-206 focus on?
The FOA focused on AIDS prophylactic vaccine discovery research. This means the emphasis was on upstream research that defines and validates vaccine concepts before they move into later-stage clinical testing.
Does this program support clinical trials?
Based on the information provided, the emphasis was discovery-stage research intended to support or inform later-stage clinical testing, rather than being described as a clinical testing FOA itself.
What kinds of disciplines or expertise were expected to be involved?
The FOA highlighted multi-disciplinary collaboration. In the HIV vaccine field, this typically includes immunology, virology, structural biology, protein engineering, antibody and B cell biology, computational or systems approaches, and translational studies that connect laboratory findings to realistic vaccine strategies.
Were non-human primate studies allowed under this opportunity?
Yes. A notable feature was that it explicitly allowed extensive modeling of vaccine concepts in non-human primates, reflecting the importance of primate studies for evaluating immune responses, protection signals, and candidate vaccine performance in a model more comparable to humans than small animals.
What type of grant opportunity was this considered to be?
It was described as a discretionary grant opportunity using the NIH grant funding instrument and categorized under health-related research.
What CFDA numbers were associated with this FOA?
The relevant CFDA numbers were 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
When was PAR-14-206 posted, and what were the key dates?
The announcement was posted on May 5, 2014. The original and final closing date was July 29, 2014. The archive date was August 29, 2014.
How much funding was available under this opportunity?
The estimated total funding available was $5,000,000. This indicates NIH expected to support a limited number of sizeable, collaborative awards rather than many small grants.
Was cost sharing or matching required?
No. There was no cost sharing or matching requirement listed for this opportunity.
Who was eligible to apply within the United States?
Eligibility for domestic applicants included a broad range of organization types: public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including small businesses and other for-profits); state and local governments (including city/township governments, county governments, and special district governments); and public housing authorities/Indian housing authorities.
Were tribal entities and tribal-serving institutions eligible?
Yes. The FOA explicitly included Federally recognized tribal governments, tribal organizations that are not Federally recognized, and Tribally Controlled Colleges and Universities (TCCUs).
Were minority-serving institutions eligible?
Yes. The FOA listed several minority-serving or tribal-serving institution categories as eligible, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Could faith-based or community-based organizations apply?
Yes. Faith-based and community-based organizations were listed among the eligible applicant organization types.
Could agencies of the Federal Government apply?
Yes. Eligible agencies of the Federal Government were listed as eligible applicants.
Could non-U.S. (foreign) organizations apply directly?
Yes. Non-domestic (non-U.S.) entities (foreign organizations) and non-domestic (non-U.S.) foreign institutions were eligible to apply.
Are foreign components of U.S. organizations allowed?
Yes. Non-U.S. components of U.S. organizations could participate, and foreign components were permitted as defined in the NIH Grants Policy Statement.
Why did the FOA allow international participation?
The information provided notes that HIV vaccine research often requires expertise, cohorts, and research infrastructure spanning multiple countries, and NIH commonly supports international collaboration when it is scientifically justified.
Where can applicants find the official FOA text?
The full announcement was available at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-206.html
Who should be contacted for technical issues accessing the announcement link?
The contact listed for technical issues accessing the announcement or linking to it was the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
In plain terms, what was the overall goal of HIVRAD P01 (PAR-14-206)?
Overall, HIVRAD P01 funding was intended to accelerate innovative, team-based HIV vaccine discovery by supporting integrated research programs capable of addressing high-impact scientific problems and, when appropriate, rigorously testing vaccine ideas in non-human primate models.
Browse more opportunities from the same category: Health
Next opportunity: Office of Special Education and Rehabilitative Services (OSERS) Rehabilitation Services Administration (RSA) Centers for Independent Living CFDA Number 84.132A
Previous opportunity: Cooperative Ecosystem Studies Unit, Gulf Coast CESU
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 206
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 206) also looked into and applied for these:
| Funding Opportunity |
|---|
| Protecting and Improving Public Health Globally Building and Strengthening Public Health Impact, Systems, Capacity and Security Apply for CDC RFA GH14 1418 Funding Number: CDC RFA GH14 1418 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01) Apply for PAR 14 207 Funding Number: PAR 14 207 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Longitudinal Assessment of Post traumatic Syndromes (U01) Apply for RFA MH 15 110 Funding Number: RFA MH 15 110 Agency: National Institutes of Health Category: Health Funding Amount: $5,000,000 |
| Enhancing situational awareness, surveillance, detection, risk assessment and response activities using a mapping and visualization tool Apply for CDC RFA CK14 1404 Funding Number: CDC RFA CK14 1404 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre Clinical Research (R44) Apply for PAR 14 209 Funding Number: PAR 14 209 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Exploratory Clinical Trials and Clinical Research (R44) Apply for PAR 14 208 Funding Number: PAR 14 208 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Affordable Care Act SHIP and ADRC Options Counseling for Medicare Medicaid Individuals in States with Approved Financial Alignment Models Apply for CMS 1N1 14 001 Funding Number: CMS 1N1 14 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $1,000,000 |
| Pharmacogenomics Knowledge Base (R24) Apply for RFA GM 15 002 Funding Number: RFA GM 15 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,600,000 |
| Local Nongovernmental Partnerships for Sustained Country Leadership in Rwanda under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1414 Funding Number: CDC RFA GH14 1414 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| FY14 Minority Youth Violence Prevention Integrating Public Health and Community Policing Approaches Apply for MP YEP 14 001 Funding Number: MP YEP 14 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $400,000 |
| NIMHD Social, Behavioral, Health Services, and Policy Research on Minority Health and Health Disparities (R01) Apply for RFA MD 14 004 Funding Number: RFA MD 14 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIMHD Basic and Applied Biomedical Research on Minority Health and Health Disparities (R01) Apply for RFA MD 14 005 Funding Number: RFA MD 14 005 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| FY14 Youth Empowerment Program II (YEP II) Apply for MP YEP 14 005 Funding Number: MP YEP 14 005 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $500,000 |
| CDCs Collaboration with Academia to Strengthen Public Health Workforce Capacity Apply for CDC RFA OE12 120103CONT14 Funding Number: CDC RFA OE12 120103CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Frontier Community Health Integration Project Technical Assistance, Tracking, and Analysis Apply for HRSA 14 137 Funding Number: HRSA 14 137 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| PPHF 2014 Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations financed in part by 2014 Prevention and Public Health Funds Apply for CDC RFA DP12 1205PPHF14 Funding Number: CDC RFA DP12 1205PPHF14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Reinvestment of Civil Money Penalties to Benefit Nursing Home Residents Apply for CMS 1K1 14 001 Funding Number: CMS 1K1 14 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $500,000 |
| Civil Society Capacity Building for Advocacy and Response to the HIV/AIDS Epidemic Among Key Populations in India under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1411 Funding Number: CDC RFA GH14 1411 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| State Based Perinatal Quality Collaboratives Apply for CDC RFA DP14 1404 Funding Number: CDC RFA DP14 1404 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Immunization and Vaccines for Children Program Apply for CDC RFA IP13 1301PPHF15 Funding Number: CDC RFA IP13 1301PPHF15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $33,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 206", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.